FRIDAY, Oct. 25, 2024 (HealthDay News) — As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023,Continue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking sevenContinue Reading
THURSDAY, Oct. 24, 2024 (HealthDay News) — Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study claims. Obesity and all its attendant ills — type 2 diabetes, heart disease and cancer amongContinue Reading
-690x550.jpg)
THURSDAY, Oct. 17, 2024 (HealthDay News) — Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1), have a 50% lower rate of drunkenness thanContinue Reading
WEDNESDAY, Oct. 16, 2024 (HealthDay News) — Obesity is a more powerful driver of breast cancer than previously thought, a new study suggests. About 40% of hormone-positive breast cancers in postmenopausal women might be linked to excess body fat, researchers reported Oct. 15 in the Journal of Epidemiology & CommunityContinue Reading
TUESDAY, Oct. 15, 2024 (HealthDay News) — Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list. What prompted the FDA to reconsider its decision? On Oct.Continue Reading
MONDAY, Oct. 14, 2024 (HealthDay News) — As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts. But a new study involving more than 54,000 U.S. adolescentsContinue Reading
MONDAY, Oct. 14, 2024 (HealthDay News) — Results from a very small study suggest that a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with type 2 diabetes. The new trial hasn’t yet been published in aContinue Reading
FRIDAY, Oct. 11, 2024 (HealthDay News) — The key to weight loss could come down to a combination of 14 “skinny genes,” a recent study says. People with these genes dropped twice as much weight through regular exercise compared to those without the genes, researchers found. Those with the mostContinue Reading
WEDNESDAY, Oct. 9, 2024 (HealthDay News) — When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows. In a report published Wednesday in the journal Health Affairs,Continue Reading